ReviewFrontiers in neurology2021
Endothelial Dysfunction and Hyperhomocysteinemia-Linked Cerebral Small Vessel Disease: Underlying Mechanisms and Treatment Timing.
Review in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Homocysteine and cognitive function in depression: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Association between methylenetetrahydrofolate reductase C677T polymorphism and cerebral small vessel disease: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Research progress on the application of functional magnetic resonance imaging in cognitive dysfunction in patients with cerebral small vessel disease.Frontiers in neurology · 2025Pooled it
- Association of low vitamin B12 status with incident dementia and stroke: an EHR database study.Frontiers in nutrition · 2026Article
- Serum cystatin C levels are independently correlated with cognitive impairment in individuals with cerebral small vessel disease.Frontiers in neuroscience · 2026Article
- Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications.Pharmaceutics · 2025Review
- Association between homocysteine and severe cerebral small vessel disease burden in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- Homocysteine, neurodegenerative biomarkers, and APOE ε4 in neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The impact of periodic leg movements during sleep on neurological recovery in patients with acute mild cerebral infarction.Frontiers in neurology · 2025Article
- Association of serum 25-hydroxyvitamin D and homocysteine "double-risk" status with executive dysfunction in older adults with hypertension.Frontiers in nutrition · 2025Article
- Analysis of the impact of cerebral small vessel disease on neurological outcomes in patients with basal ganglia/corona radiata ischemic stroke treated with intravenous thrombolysis under multimodal MRI guidance.Frontiers in neurology · 2025Article
- Identifying gut microbiota with high specificity for ischemic stroke with large vessel occlusion.Scientific reports · 2024Article
- Exploring the neuroprotective role of physical activity in cerebral small vessel disease.Brain research · 2024Review
- Methylenetetrahydrofolate reductase polymorphisms and elevated plasma homocysteine levels in small vessel disease.Brain and behavior · 2023Article
- Plasma inflammatory biomarkers in cerebral small vessel disease: A review.CNS neuroscience & therapeutics · 2023Review
- Impact of cerebral small vessel disease burden and systemic clinical phenotypes on short-term neurological outcomes after acute ischemic stroke.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral small vessel disease (cSVD)-a common cause of stroke and vascular dementia-is a group of clinical syndromes that affects the brain's small vessels, including arterioles, capillaries, and venules. Its pathogenesis is not fully understood, and effective treatments are limited. Increasing evidence indicates that an elevated total serum homocysteine level is directly and indirectly associated with cSVD, and endothelial dysfunction plays an active role in this association. Hyperhomocysteinemia affects endothelial function through oxidative stress, inflammatory pathways, and epigenetic alterations at an early stage, even before the onset of small vessel injuries and the disease. Therefore, hyperhomocysteinemia is potentially an important therapeutic target for cSVD. However, decreasing the homocysteine level is not sufficiently effective, possibly due to delayed treatment, which underlying reason remains unclear. In this review, we examined endothelial dysfunction to understand the close relationship between hyperhomocysteinemia and cSVD and identify the optimal timing for the therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.